Your browser doesn't support javascript.
loading
Two Cases of Frontal Variation of Idiopathic Calvarial Thinning-Therapeutic Effect of Denosumab and Romosozumab.
Baek, Seungjin; Hong, Namki; Rhee, Yumie.
Afiliación
  • Baek S; Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Hong N; Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Rhee Y; Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
JCEM Case Rep ; 1(6): luad122, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37954836
ABSTRACT
Idiopathic calvarial thinning is a rare condition that causes progressive, painless thinning of the skull bones without systemic disease. We present 2 cases of idiopathic calvarial thinning involving the bifrontal region. Both patients exhibited forehead depression and had normal biochemical tests except for mild vitamin D deficiency. The first patient received treatment with denosumab for 3 years, showing no further progression of the skull thinning. The second patient was treated with denosumab for 3 years, followed by romosozumab for 1 year, resulting in no further progression and even slight recovery of the skull thickness. These cases demonstrate that idiopathic calvarial thinning can involve the bifrontal region and highlight the favorable treatment and prognosis with denosumab or romosozumab.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JCEM Case Rep Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JCEM Case Rep Año: 2023 Tipo del documento: Article